PFND — Pathfinder Cell Therapy Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2010 | 2011 | 2012 | 2013 | 2014 | 2015E | 2016E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 0.07 | 0.11 | 0.05 | n/a | n/a | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Pathfinder Cell Therapy, Inc. is a regenerative medicine company. The Company is seeking to develop cell-based and related therapies for the treatment of a range of diseases and medical conditions characterized by organ-specific cell damage. The Company is engaged in developing cell-based therapy for the treatment of diabetes, renal disease, myocardial infarction and other diseases characterized by organ-specific cell damage. The Company has discovered a mammalian cell type, which is able to stimulate damaged tissues to regenerate without the Pathfinder Cells (PCs) themselves being incorporated into the new tissue. PCs have shown efficacy in approximately three different animal models of diabetes, cardiac ischemia and renal reperfusion injury. The Company has tested these models for PCs from both rat and human sources. As of September 30, 2015, the Company had no revenue generated.
Directors
- Joerg Gruber CHM (54)
- Richard Franklin CEO (69)
- John Benson CFO (53)
- John Alam IND (53)
- John Brooks IND
- Zen Chu IND (43)
- Brock Reeve IND (58)
- Last Annual
- December 31st, 2014
- Last Interim
- September 30th, 2015
- Incorporated
- August 1st, 1990
- Public Since
- September 22nd, 1992
- No. of Employees
- 1
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 667,160,870
- Address
- 12 Bow St, CAMBRIDGE, 02138
- Web
- http://www.pathfindercelltherapy.com/
- Phone
- +1 6172450289
- Contact
- Richard Franklin
- Auditors
- EisnerAmper LLP
Upcoming Events for PFND
Similar to PFND
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
As of Today at 22:35 UTC, shares in Pathfinder Cell Therapy are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Pathfinder Cell Therapy last closed at $0.00 and the price had moved by -99% over the past 365 days. In terms of relative price strength the Pathfinder Cell Therapy share price has underperformed the S&P500 Index by -99.16% over the past year.
There is no consensus recommendation for this security.
Find out morePathfinder Cell Therapy does not currently pay a dividend.
Pathfinder Cell Therapy does not currently pay a dividend.
Pathfinder Cell Therapy does not currently pay a dividend.
To buy shares in Pathfinder Cell Therapy you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Pathfinder Cell Therapy had a market capitalisation of .
Here are the trading details for Pathfinder Cell Therapy:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: PFND
Based on an overall assessment of its quality, value and momentum Pathfinder Cell Therapy is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pathfinder Cell Therapy. Over the past six months, its share price has underperformed the S&P500 Index by -5.16%.
As of the last closing price of $0.00, shares in Pathfinder Cell Therapy were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Pathfinder Cell Therapy PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Pathfinder Cell Therapy's management team is headed by:
- Joerg Gruber - CHM
- Richard Franklin - CEO
- John Benson - CFO
- John Alam - IND
- John Brooks - IND
- Zen Chu - IND
- Brock Reeve - IND